RA
CHRS icon

Royce & Associates’s Coherus Oncology CHRS Stock Holding History

Royce & Associates’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-106,700
Closed -$399K – 875
2023
Q3 		$399K Hold
106,700
– – ﹤0.01% 831
2023
Q2 		$456K Hold
106,700
– – ﹤0.01% 848
2023
Q1 		$730K Hold
106,700
– – 0.01% 807
2022
Q4 		$845K Sell
106,700
-2,577
-2% -$19.8K 0.01% 777
2022
Q3 		$1.05M Sell
109,277
-12,507
-10% -$127K 0.01% 729
2022
Q2 		$882K Sell
121,784
-21,163
-15% -$184K 0.01% 768
2022
Q1 		$1.84M Buy
142,947
+94,318
+194% +$1.2M 0.02% 723
2021
Q4 		$776K Sell
48,629
-98,394
-67% -$1.72M 0.01% 836
2021
Q3 		$2.36M Buy
147,023
+18,386
+14% +$269K 0.02% 720
2021
Q2 		$1.78M Buy
128,637
+1,164
+0.9% +$16.5K 0.01% 774
2021
Q1 		$1.86M Sell
127,473
-212,999
-63% -$3.62M 0.01% 763
2020
Q4 		$5.92M Sell
340,472
-30,042
-8% -$535K 0.05% 513
2020
Q3 		$6.79M Buy
370,514
+14,899
+4% +$277K 0.07% 398
2020
Q2 		$6.35M Buy
355,615
+57,103
+19% +$967K 0.07% 398
2020
Q1 		$4.84M Buy
+298,512
New +$5.52M 0.07% 386

Other funds holding CHRS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royce & Associates's CHRS Position: Q4 2023 in Review

Royce & Associates sold out of Coherus Oncology (CHRS) in Q4 2023, closing a stake of 106,700 shares — an estimated $399K sold.

Royce & Associates first reported a position in CHRS in Q1 2020 and held it in 15 quarters. The position peaked at $6.79M in Q3 2020. 156 funds tracked by Wall St. Rank hold CHRS as of Q4 2023.

  • Royce & Associates reported no remaining Coherus Oncology position as of Q4 2023 after selling out during the quarter.
  • Royce & Associates sold 106,700 Coherus Oncology shares in Q4 2023, an estimated $399K.
  • Royce & Associates first reported a position in Coherus Oncology in Q1 2020 and held it in 15 quarters.
  • Royce & Associates's Coherus Oncology position peaked at $6.79M in Q3 2020.
  • 156 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2023.

Based on Royce & Associates's 13F filing for Q4 2023, filed 12 Feb 2024.